Discovery of a novel class of AKT pleckstrin homology domain inhibitors

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2621-2632

  Mahadevan, Daruka ^a   Powis, Garth ^e   Mash, Eugene A ^c   George, Benjamin ^b   Gokhale, Vijay M ^b   Zhang, Shuxing ^e   Shakalya, Kishore ^a   Du Cuny, Lei ^e   Berggren, Margareta ^b   Ali, M Ahad ^c   Jana, Umasish ^c   Ihle, Nathan ^e   Moses, Sylvestor ^d   Franklin, Chloe ^e   Narayan, Satya ^a   Shirahatti, Nikhil ^a   Meuillet, Emmanuelle J ^b,d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c University of Arizona   (United States)

^d University of Arizona   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 (4 CHLOROBENZOYL) 3 METHYL 5 OXO 4,5 DIHYDRO 1H PYRAZOL 4 YLAZO] N PYRIMIDINE 2 YL BENZENESULFONAMIDE; ANTINEOPLASTIC AGENT; INSULIN RECEPTOR SUBSTRATE 1; NSC 348900; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PLECKSTRIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL PROLIFERATION; COLON CANCER; COMPUTER MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ELIMINATION; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SCREENING; SURFACE PLASMON RESONANCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HT29 CELLS; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; SEQUENCE ALIGNMENT; THIEPINS;

EID: 54049116732     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2276     Document Type: Article

References (48)

1. Workman P, Clarke PA, Guillard S, Raynaud FI. Drugging the PI3 kinome. Nat Biotechnol 2006;24:794-6.
2. Hennessy BT, Smith DL, Ram PT, Lu Yling Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2004;4:988-1004.
3. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-8.
4. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/ MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1998;95:15587-91.
5. Cantley L, Neel BG. New insights into tumor suppression: PTEN suppress tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathways. Proc Natl Acad Sci U S A 1999;96:4240-5.
6. Marte BM, Downward J. PKB/AKT: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 1997;22:355-8.
7. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-AKT): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 1998;335:1-13.
8. Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of AKT3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21525-32.
9. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998;8:55-62.
10. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/AKT. FEBS Lett 2003;546:108-12.
11. Scheid MP, Woodgett JR. PKb/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2001;2:760-8.
12. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Ba. Curr Biol 1997;7:261-9.
13. Delcommenne M, Tan C, Gray V, et al. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/ AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A 1998;95:11211-6.
14. Sarbassov dos D, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of PKB by the mTor-rictor complex. Science 2005;307:1098-101.
15. Kawakami Y, Nishimoto H, Kitaura J, et al. Protein kinase ChII regulates AKT phosphorylation on Ser-473 in a cell type and stimulus specific fashion. J Biol Chem 2004;279:47720-5.
16. Yang ZZ, Tschopp O, Hemmings-Mieszczak M, et al. Protein kinase Bα/AKT1 regulates placental growth and fetal growth. J Biol Chem 2003;278:32124-31.
17. Meier R, Alessi DR, Cron P, Andjelkovic M, Hemmings BA. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bβ. J Biol Chem 1997;272:30491-7.
18. Nicholson KM, Anderson NG. The protein kinase B/AKT signaling pathway in human malignancy. Cell Signal 2002;14:381-95.
19. Datta SR, Dudek H, Tao X, et al. AKT phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
20. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. AKT phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001;21:893-901.
21. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-21.
22. Ozes ON, Mayo LD, Gustin JA, et al. NF-κB activation by tumour necrosis factor requires the AKT serine-threonine kinase. Nature 1999;401:82-5.
23. Du K, Montminy M. CREB is a regulatory target for the protein kinase AKT/PKB. J Biol Chem 1998;273:32377-9.
24. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994;370:71-5.
25. van Weeren PC, de Bruyn KM, de Vries-Smits AM, Van Lint J, Burgering BM. Essential role for protein kinase B(PKB) in insulin-induced glycogen synthase kinase 3 inactivation: characterization of dominant-negative mutant of PKB. J Biol Chem 1998;273:13150-6.
26. Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiangenic drugs: implications for the use of combination therapy approaches. Cancer Metast Rev 2001;20:79-86.
27. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol-3 kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
28. Rebecchi MJ, Scarlata S. Pleckstrin homology domains: a common fold with diverse functions. Annu Rev Biophys Biomol Struct 1998;27:503-28.
29. Touhara K, Inglese J, Pitcher JA, Shaw G, Lefkowitz RJ. Binding of G protein βγ-subunits to pleckstrin homology domains. J Biol Chem 1994;269:10217-20.
30. Mahadevan D, Thank N, Singh J, et al. Structural studies of the PH domains of Dbl, SOs1, IRS-1 and βARK1 and their differential binding to Gβγ subunits. Biochemistry 1995;34:9111-7.
31. Czech MP. Pip2 and pip3: complex roles at the cell surface. Cell 2000;100:603-6.
32. Thomas CC, Deak M, Alessi DR, van Aalten DM. High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol 2002;12:1256-62.
33. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44.
34. Feldman R, Wu J, Polokoff M, et al. Novel small molecule inhibitors of 3′-phosphoinositide-dependent kinsase1 (PDK-1). Eur J Cancer 2004;2:77.
35. Giranda V, Luo Y, Li Q, et al. Novel ATP-competitive AKT inhibitors slow the progression of tumors in vivo. Eur J Cancer 2004;2:77.
36. Meuillet EJ, Mahadevan D, Vankayalapati H, et al. Specific inhibition of the AKT1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myoinositol analogs. Mol Cancer Ther 2003;2:389-99.
37. Meuillet EJ, Ihle N, Baker AF, et al. In vivo molecular pharmacology and antitumor activity of the targeted AKT inhibitor PX-316. Oncol Res 2004;14:513-27.
38. Wang R, Lai L, Wang S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des 2002;16:11-26.
39. Dhe-Paganon S, Ottinger EA, Nolte RT, Eck MJ, Shoelson SE. Crystal structure of the pleckstrin homology-phosphotyrosine binding (PH-PTB) targeting region of insulin receptor substrate 1. Proc Natl Acad Sci U S A 1999;96:8378-83.
40. Komander D, Fairservice A, Deak M, et al. Structural insights into the regulation of Pdk1 by phosphoinositides and inositol phosphates. EMBO J 2004;23:3918-28.
41. Powell AA, LaRue JM, Batta AK, Martinez JD. Bile acid hydrophobicity is correlated withinduction of apoptosis and/or growth arrest in HCT116 cells. Biochem J 2001;356:481-6.
42. Paine-Murrieta GD, Taylor CW, Curtis RA, et al. Human tumor models in the severe combined immune deficient scid mouse. Cancer Chemother Pharmacol 1997;40:209-14.
43. Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene 2005;24:7493-501.
44. Catley L, Hideshima T, Chauhan D, et al. Alkyl phospholipids perifosine induces myeloid hyperplasia in a murin myeloma model. Exp Hematol 2007;35:1038-46.
45. Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs 2005;6:1250-8.
46. Gills J, Holbeck S, Hollingshead M, et al. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther 2006;5:713-22.
47. Castillo SS, Brognard J, Petukhov PA, et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phophatidylinositol ether lipid analogues. Cancer Res 2004;64:2792-92.
48. Calleja V, Alcor D, Laguerre M, et al. Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol 2007;5:e95.